Segment Information and Concentration of Customers and Suppliers (Tables)

12 Months Ended

Dec. 31, 2013

Segment Information and Concentration of Customers and Suppliers

Schedule of revenue

Revenue was as follows for the years ended December 31, 2013, 2012 and 2011 (in thousands):

	2013		2012
Net product revenue:
Qsymia	$	23,718	$	2,012
STENDRA or SPEDRA		1,526		—
Total net product revenue		25,244		2,012
License revenue		55,838		—
Total revenue	$	81,082	$	2,012

Schedule of geographic information with respect to revenues

Total revenue by geographic region for the years ended December 31, 2013 and 2012, was as follows (in thousands):

	Years Ended December 31,
	2013					2012
	U.S		ROW			U.S		ROW
Qsymia—Net product revenue	$	23,718	$	—		$	2,012	$	—
STENDRA/SPEDRA—Net product revenue		1,080		446			—		—
Total net product revenue		24,798		446			2,012		—
STENDRA/SPEDRA—License revenue		30,393		25,445	(1)		—		—
Total revenue	$	55,191	$	25,891		$	2,012	$	—

(1)

$21.0 million of which is attributable to Germany.

Total revenues | Customer concentration

Concentration of Customers

Schedule of significant customers concentration

	2013			2012
Auxilium		39	%		—	%
Menarini		26	%		—	%
CVS		9	%		50	%
Walgreens		6	%		39	%
Express Scripts, Inc.		3	%		10	%

Gross accounts receivable | Credit concentration

Concentration of Customers

Schedule of significant customers concentration

	2013			2012
Menarini		41	%		—	%
Amerisource Bergen		26	%		—	%
McKesson		13	%		—	%
Cardinal Health, Inc.		12	%		—	%
CVS		1	%		51	%
Walgreens		1	%		44	%
Express Scripts, Inc.		1	%		1	%